Did you know ? If you order before Friday 14h we deliver 90PCT of the the time next Tuesday, GENTAUR another in time delivery

Pubmed ID :29697098
Publication Date : //

A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.


BACKGROUND Combined chemotherapy and radiation therapy are used to treat nasopharyngeal carcinoma (NPC). Previous studies have shown that induction chemotherapy, given before radiotherapy, is beneficial in patients with local lymph node metastases. The aim of this study was to evaluate regional lymph node size in patients with NPC and the efficacy of five induction chemotherapy regimens given before radiotherapy. MATERIAL AND METHODS Between December 2007 and June 2011, 190 patients were included in this study, who had regionally advanced NPC (Stages II-IV). Five induction chemotherapy regimens were given prior to radiation: 98 patients (51.6%) received the TPF regimen (docetaxel, cisplatin, and fluorouracil); 56 patients (29.5%) received PF regimen (cisplatin and fluorouracil); 26 patients (13.7%) received the TP regimen (cisplatin and docetaxel); seven patients (3.7%) received combined nimotuzumab with TPF; three patients (1.6%) received a combination of the novel modified recombinant human endostatin (Endostar) with PF. The length and width of the regional lymph nodes were measured using neck B-mode (high-resolution grey scale) ultrasonography before chemotherapy and on the second day following completion of chemotherapy. Gastrointestinal tract and bone marrow suppression were also monitored during and after chemotherapy. RESULTS The TPF chemotherapy induction regimen resulted in an improved early response of lymph node size reduction, compared with the PF and TP chemotherapy induction regimens. The combined use of nimotuzumab with the TPF regimen improved efficacy by 15%. The combined use of Endostar improved the efficacy of the PF regimen by 56% (P<0.05). CONCLUSIONS In a retrospective study in patients with NPC, different induction chemotherapy regimens had different effects on lymph node size before radiation therapy.

Authors : Chen Jing , Qi Ji , Yu Bolong , Peng Xiao-Hong , Wang Fan , Tan Jia-Jie , Chen Qi-Qian , Peng Xin-Yu , Zeng Fang-Fang , Liu Xiong ,

Related products :

Catalog number Product name Quantity
933 Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002
CO1002b Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002
CO1002b Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002
CO1002b Colorectal carcinoma and matched adjacent normal tissue array with lymph node metastasis carcinoma, including TNM and pathology grade, 64 cases_100 cores, replacing CO1002; ihc Anti-Actin confirmed
LY802 Lymph node metastatic squamous cell carcinoma tissue array, 80 cases_80 cores
BR1005 Breast cancer and matched metastatic carcinoma of lymph node, 50 cases_100 cores, no overlaps with BR1001 or BR1004
LY802 Lymph node metastatic squamous cell carcinoma tissue array, 80 cases_80 cores; ihc Anti-Cytokeratin (CK) confirmed
EIAAB27645 Homo sapiens,Human,Nasopharyngeal carcinoma down-regulated gene protein 1,Nasopharyngeal carcinoma-related gene protein,NPCDR1,NPCDRG,NPCR
BR1005 Breast cancer and matched metastatic carcinoma of lymph node, 50 cases_100 cores, no overlaps with BR1001 or BR1004, replaced by BR1005a; ihc Anti-Actin confirmed
1124 Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BR1005
T2235161-3 Paraffin Tissue Section - Human Lymph Nodes Tumor: Reactive Hyperplasia of Lymph Node 5 slides
EIAAB07019 Brain and nasopharyngeal carcinoma susceptibility protein NSG-x,C7orf54,Homo sapiens,Human,NAG8,Nasopharyngeal carcinoma-associated gene 8 protein,Uncharacterized protein C7orf54
LYS081B HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 1 mg
SCH-LYS081 HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 0.1 mg
SCH-LYS081A HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 0.5 mg
LYS081A HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 0.5 mg
LYS081 HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 0.1 mg
SCH-LYS081B HUMAN LYMPH NODE TOTAL PROTEIN LYSATE, Product Type Cell Lysate, Specificity LYMPH NODE LYSATE, Target Species Human, Host N_A, Format Total Protein Lysate, Isotypes , Applications WB, Clone 1 mg
BR1005a Breast cancer and matched metastatic carcinoma of lymph node tissue array, including TNM, clinical stage and pathology grade, 50 cases_100 cores, replacing BR1005; ihc Anti-Actin confirmed
Tissues-123-LYMPH NODE Human Tissues - LYMPH NODE 1unit
21-307 Lymph node Lysate 0.2 mg
BMN-15 MouseNormalTisLysDIP_N_BLOT (Lymph Node) 1 strip
BMN-15 MouseNormalTisLysDIP_N_BLOT (Lymph Node) 1 strip
BMN-15 MouseNormalTisLysDIP_N_BLOT (Lymph Node) 1 strip
21-307 Lymph node Lysate 1.0 mg


 

GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45

Fax 0032 16 50 90 45
info@gentaur.com | Gentaur





GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
uk@gentaur.com | Gentaur

 

 




GENTAUR France SARL
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50

Fax 01 43 25 01 60
RCS Paris B 484 237 888

SIRET 48423788800017

BNP PARIBAS PARIS PL MAUBERT BIC BNPAFRPPPRG

france@gentaur.com | Gentaur

GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Support Karolina Elandt
Tel: 0035929830070
Fax: (+49) 241 56 00 47 88

Logistic :0241 40 08 90 86
Bankleitzahl 39050000
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
Steuernummer 201/5961/3925
de@gentaur.com | Gentaur

GENTAUR U.S.A
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
sales@genprice.com

Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123




GENTAUR Nederland BV
NL850396268B01 KVK nummer 52327027
Kuiper 1
5521 DG Eersel Nederland
Tel:  0208-080893  Fax: 0497-517897
nl@gentaur.com | Gentaur
IBAN: NL04 RABO 0156 9854 62   SWIFT RABONL2U






GENTAUR Spain
tel:0911876558
spain@gentaur.com | Gentaur






ГЕНТАУЪР БЪЛГАРИЯ
ID # 201 358 931 /BULSTAT
София 1000, ул. "Граф Игнатиев" 53 вх. В, ет. 2
Tel 0035924682280 Fax 0035924808322
e-mail: Sofia@gentaur.com | Gentaur
IBAN: BG11FINV91501014771636
BIC: FINVBGSF

GENTAUR Poland Sp. z o.o.


ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
TEL Gdansk 058 710 33 44 FAX  058 710 33 48              

poland@gentaur.com | Gentaur

Other countries

Österreich +43720880899

Canada Montreal +15149077481

Ceská republika Praha +420246019719

Danmark +4569918806

Finland Helsset +358942419041

Magyarország Budapest +3619980547

Ireland Dublin+35316526556

Luxembourg+35220880274

Norge Oslo+4721031366

Sverige Stockholm+46852503438

Schweiz Züri+41435006251

US New York+17185132983

GENTAUR Italy
SRL IVA IT03841300167
Piazza Giacomo Matteotti, 6
24122 Bergamo Tel 02 36 00 65 93
Fax 02 36 00 65 94
italia@gentaur.com | Gentaur